To be honest I do not see ONCS turning into a big pharma. I think if and after combo efficiency and value are proven in melanoma, Merck will buy it out paying a premium for other indications which it can further on its own. I do not want to stay for 3-4 years for each indication. A lump sum buyout would be fine by me.